Receptor.AI is a TechBio drug discovery company with a validated record across more than 40 discovery programs, guided by domain experts with FDA-approved therapeutics. Our integrated multi-platform ecosystem spanning small molecules, peptides, and induced-proximity therapeutics enables the systematic design of candidates with optimized safety, potency, and translational performance.

As a full-stack drug discovery organization, we conduct end-to-end R&D from de novo hit generation through lead optimization and IND-enabling stages using our proprietary platforms for peptides, small molecules and antibodies. Our discovery engine unites QuorumMap, which navigates vast and novel chemical space to identify differentiated starting points, with AdmetIQ, our system for real-time multiparametric ADMET and developability optimization.